Evidence map›Paper›PMID 38464491›Full record

ArticleOpen forum infectious diseases2024

Pretreatment and Acquired Drug Resistance in Children With Human Immunodeficiency Virus Type 1 in Jos, Nigeria.

Augustine O Ebonyi, Jonathan Okpokwu, Holly Rawizza, Philippe Chebu, Beth Chaplin, Donald Hamel, Stephen Oguche, Oche O Agbaji, Atiene S Sagay, Phyllis J Kanki and 1 more

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Augustine O EbonyiDepartment of Paediatrics, University of Jos, Jos University Teaching Hospital, Jos, Nigeria.
Jonathan OkpokwuAIDS Prevention Initiative in Nigeria-supported ISO 15189 Laboratory, Jos University Teaching Hospital, Jos, Nigeria.
Holly RawizzaDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0003-3599-1468
Philippe ChebuAPIN Public Health Initiatives, Plot 1551, Apo Resettlement, Apo District, Abuja, FCT, Nigeria.
Beth ChaplinDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Donald HamelDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Stephen OgucheDepartment of Paediatrics, University of Jos, Jos University Teaching Hospital, Jos, Nigeria.
Oche O AgbajiDepartment of Medicine, University of Jos, Jos University Teaching Hospital, Jos, Nigeria.
Atiene S SagayDepartment of Obstetrics and Gynaecology, University of Jos, Jos University Teaching Hospital, Jos, Nigeria.
Phyllis J KankiDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Godwin E ImadeAIDS Prevention Initiative in Nigeria-supported ISO 15189 Laboratory, Jos University Teaching Hospital, Jos, Nigeria.ORCID https://orcid.org/0000-0001-5221-7699
University of Jos · NGHarvard University · USAIDS Prevention Initiative in Nigeria · NG

Funding

Support of Training and Mentoring in Nigeria for Academics (STAMINA)D43TW010130 · FIC · UNIVERSITY OF JOS · PI SAGAY, ATIENE SOLOMON · 2015 to 2019
$3.2M
Acquired HIV drug resistance among Nigerian children failing first-line ART: Implications for second-line dolutegravir useR21AI162201 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI RAWIZZA, HOLLY ELIZABETH · 2021 to 2022
$379k
FIC NIH HHS D43 TW010130NIAID NIH HHS R21 AI162201
6 · The paper itself

Abstract

We determined pretreatment and acquired human immunodeficiency virus (HIV) drug resistance among children with HIV type 1 (HIV-1) in Jos, Nigeria. The majority (71%) of those who failed first-line antiretroviral therapy were on a nevirapine-containing regimen. The prevalence of pretreatment (48%) and acquired (76%) HIV drug resistance mutations was high in our study. Wider access to HIV drug resistance testing after treatment failure is necessary to optimize second-line treatment options among children with HIV in Nigeria.

Indexed as

childrendrug resistanceHIV-1mutationsNigeria

Identifiers

PMID38464491
PMCPMC10921386
OpenAlexW4391947764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.